New hope to shield kidneys in High-Risk liver transplants
NCT ID NCT06344442
Summary
This study is testing if giving a low dose of a natural hormone called arginine-vasopressin (AVP) during liver transplant surgery can better protect patients' kidneys afterward. It will compare AVP against the standard medication (norepinephrine) in 304 adults getting a liver transplant. The goal is to see if AVP can lower the high rate of serious kidney injury that often follows this major surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY POST LIVER TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
URC Lariboisière-Fernand Widal-saint Louis
RECRUITINGParis, 75010, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.